Aspen has launched one of the world’s largest hubs for the manufacturing of general anaesthetic products at its manufacturing site in Gqeberha in the Eastern Cape. Established through the company’s R3.4 billion investment in the province, the facility was officially opened by the Minister of Trade, Industry and Competition, Ebrahim Patel this week. It follows three months after Aspen became the contracted manufacturer of Johnson & Johnson’s Covid-19 vaccine in South Africa
Aspen Group Chief Executive, Stephen Saad called the opening of the anaesthetics manufacturing line a significant milestone for the company.
“This is one of the world’s largest general anaesthetics production lines and it positively positions Aspen’s integrated supply, marketing, and sale of anaesthetics globally. Our investment of more than R3.0 billion in this facility is the single largest investment in the pharmaceutical industry in the country and aligns with our commitment to supporting the industrialisation of South Africa,” Saad said.
According to Patel, the start of operations is timely as anaesthetics also supports the treatment of COVID-19 patients on ventilators in intensive care units.
“South Africa has to date imported the general anaesthetics needed in our healthcare system and the new production line will provide an important medical product for the local market, assuring security of supply, and the bulk of it will be exported across the world, contributing to global patient support,” Patel said.
Sterile Focus Brands, comprising anaesthetic and thrombosis products, is one of Aspen’s key business segments and contributes 28% of revenue. The general anaesthetics production line extends Aspen’s sterile footprint and complements the Group’s strategic vision of delivering quality, affordable medicines using high-technology pharmaceutical equipment, contributing to improved health outcomes for patients.